AGIOS PHARMACEUTICALS, INC. (AGIO) — SEC Financial Statements & Analysis

AGIOS PHARMACEUTICALS, INC. (AGIO) is a pharmaceutical preparations company, incorporated in DE. AGIOS PHARMACEUTICALS, INC. trades on Nasdaq as: AGIO. AGIOS PHARMACEUTICALS, INC. (AGIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, AGIOS PHARMACEUTICALS, INC. carries a market cap of $2.21B, a P/E ratio of -5.37x, a P/B ratio of 2.15x, a P/S ratio of 22.45x, an enterprise value of $2.11B, and an EV/EBITDA multiple of -4.59x. On profitability, it posts a gross margin of 91.99%, an operating margin of -466.78%, a net margin of -418.24%, a Return on Equity (ROE) of -34.34%, a Return on Assets (ROA) of -31.89%, and a Return on Invested Capital (ROIC) of -41.33%. Per share, it reports EPS of $-6.91, diluted EPS of $-6.91, free cash flow per share of $-6.14, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 140.58% year-over-year, net income growth of -163.27% year-over-year, and EPS growth of -161.61% year-over-year. On the balance sheet, it maintains a current ratio of 10.22x, a quick ratio of 9.06x, working capital of $647.45M, a debt-to-equity ratio of 0.08x, a debt ratio of 0.07, an interest coverage ratio of -9.91x, free cash flow of $-365.25M (TTM), and net debt of $-99.65M. Figures sourced from SEC EDGAR.

Market Cap

$2.21B

P/E TTM

-5.37x

EPS TTM

$-6.91

P/B TTM

2.15x

ROE TTM

-34.34%

ROA TTM

-31.89%

Debt To Equity

0.08x

Free Cash Flow TTM

$-365.25M

Net Revenue TTM Growth 1Y

140.58%

Data as of 2026-06-30 · Source: SEC EDGAR